Analysts have been eager to weigh in on the Healthcare sector with new ratings on QuidelOrtho (QDEL – Research Report), Ligand Pharma (LGND – Research Report) and Bioventus (BVS – Research Report).
QuidelOrtho (QDEL)
In a report released today, William Bonello from Craig-Hallum maintained a Hold rating on QuidelOrtho. The company’s shares closed last Friday at $42.50, close to its 52-week low of $37.78.
According to TipRanks.com, Bonello is a 5-star analyst with an average return of
QuidelOrtho has an analyst consensus of Hold, with a price target consensus of $59.00.
See today’s best-performing stocks on TipRanks >>
Ligand Pharma (LGND)
In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Ligand Pharma. The company’s shares closed last Friday at $73.90.
According to TipRanks.com, Hewitt is a 1-star analyst with an average return of
Ligand Pharma has an analyst consensus of Strong Buy, with a price target consensus of $116.33, a 58.2% upside from current levels. In a report issued on April 23, Barclays also maintained a Buy rating on the stock with a $110.00 price target.
Bioventus (BVS)
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Bioventus today. The company’s shares closed last Friday at $3.97.
According to TipRanks.com, Knickerbocker is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bioventus with a $7.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on QDEL:
- QDEL Earnings this Week: How Will it Perform?
- Class Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) Seeking Recovery for Investors – Contact Levi & Korsinsky LLP
- QuidelOrtho news does not help investor sentiment, says William Blair
- QuidelOrtho submission delay does not change thesis, says RBC Capital
- QuidelOrtho down 9% to $42.90 after withdrawing submission for RVP4+ assay
